Autoimmune Diseases
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global autoimmune disease drug development, market trends, and regulatory landscapes. Inform your pharma strategy.
Showing 1–11 of 11 articles
Quick answer
NovaPharmaNews Autoimmune Diseases hub for FDA covers 11 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024
Rallybio Pursues Reverse Merger with Avenzo Therapeutics to Advance Autoimmune Pipeline
UCB Acquires Antibody Treatment Maker: Implications for Autoimmune Disease Market
InnoCare Pharma Begins Phase III Trial of Orelabrutinib for Systemic Lupus Erythematosus Treatment
ACRP 2026: Immunology Clinical Research Trends to Watch
COFEPRIS Biocomparables Pathway: What You Need to Know
Biosimilar Competition Impact: US Biologics Market Analysis 2026
Nkarta Receives FDA Approval for Outpatient NKX019 Dosing in Autoimmune Disease Treatment
FDA Approves Litfulo: Key Facts on Pfizer’s Alopecia Treatment
FDA Approves First Interchangeable Humira Biosimilar: Key Details
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.